

***Fiscal Year 2021 Scleroderma Research Program (SRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-SRP-IDA</p>	<p>Independent investigators at all academic levels (or equivalent).</p> <p>New Investigators:</p> <ul style="list-style-type: none"> • Terminal degree must be within the last 10 years. • Must not have received National Institutes of Health R01 funding. • Must not have received a New Investigator Award previously from any program within the CDMRP. 	<ul style="list-style-type: none"> • Supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries in scleroderma research and/or improvements in patient care. • Innovation and impact are important aspects of the award. • Research must address at least one of the SRP FY21 Idea Development Award Focus Areas. • Preliminary data are required and need not be from the scleroderma research field. • <i>Clinical trials are not allowed.</i> • <i>New Investigator Collaboration Option:</i> Supports the continued development of promising independent investigators that are early in their faculty appointment through collaboration with an established scleroderma investigator. <u>The Initiating Principal Investigator must be the New Investigator.</u> 	<p>The maximum allowable funding for the entire period of performance is \$300,000 for direct costs.</p> <p>New Investigator Collaboration Option:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$450,000 for direct costs. • At least fifty percent of the funding must be allocated to the new investigator. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Letter of Intent): August 18, 2021 5:00 p.m. Eastern time (ET)</p> <p>Application: September 1, 2021 11:59 p.m. ET</p>

***Fiscal Year 2021 Scleroderma Research Program (SRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Translational Research Partnership Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: W81XWH-21-SRP-TRPA</p>	<p>Clinicians must be an M.D., D.O. or equivalent with clinical duties and/or responsibilities.</p> <p>At least one member of the partnership must have experience in either scleroderma research or scleroderma patient care as demonstrated by active funding and/or recent publications.</p>	<ul style="list-style-type: none"> • Supports partnerships between clinicians, research scientists and/or other disciplines that accelerate the movement of promising ideas in scleroderma research into clinical applications. At least one partner must be a clinician. • Preliminary data are required but need not be from the scleroderma research field. • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • The maximum period of performance is 3 years. • The maximum allowable funding for the entire period of performance is \$750,000 in direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. 	<p>Pre-Application (Letter of Intent): August 18, 2021 5:00 p.m. Eastern time (ET)</p> <p>Application: September 1, 2021 11:59 p.m. ET</p>